BTIG analyst Thomas Shrader reiterated a Buy rating and $29.00 price target on Stoke Therapeutics (NASDAQ: STOK)The analyst comments "Release ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE